Psychedelic Research in
Sweden
Blossom currently tracks 8 psychedelic clinical trials connected to Sweden, including 1 active study. The country page also links to 12 stakeholders and 1 event, giving the page ecosystem context beyond registered studies.
Key Insights
A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Sweden.
- 1
Blossom tracks 8 psychedelic clinical trials connected to Sweden, including 1 active study.
- 2
Visible trial compounds include Esketamine, Ketamine and Psilocybin.
- 3
Visible trial topics include Treatment-Resistant Depression (TRD), Major Depressive Disorder (MDD) and Depressive Disorders.
- 4
The country page links to 12 stakeholders and 1 event in Blossom's ecosystem data.
- 5
The country access guide currently classifies access as "Medical Only (Private)"; details vary by compound and care setting.
Research Snapshot
Blossom currently tracks 8 psychedelic clinical trials connected to Sweden, including 2 active studies.
- Active trials
- 2
- Total trials
- 8
- Stakeholders
- 12
- Events
- 1
Currently active in Blossom
Country-linked records
Linked organisations
Linked event records
Top Compounds
- Esketamine(4)
- Ketamine(2)
- Psilocybin(2)
Top Study Topics
- Treatment-Resistant Depression (TRD)(4)
- Major Depressive Disorder (MDD)(3)
- Depressive Disorders(1)
Active Trial Preview
View all trials →Medical Access Snapshot
Sweden maintains a restrictive narcotics framework: classical and novel psychedelics (psilocybin, MDMA, DMT, mescaline and most tryptamines) are controlled and have no routine medical/reimbursed use outside approved clinical research. Esketamine (Spravato) is authorised in the EU and has been the subject of Swedish health-economics assessment; access is limited to specialist psychiatry with supervised administration and regional/clinic-level funding decisions. Ketamine is an authorised anaesthetic and used in Swedish clinical research and some...
Regulatory Status
The linked medical access and reimbursement guide summarises Sweden as "Medical Only (Private)". Sweden maintains a restrictive narcotics framework: classical and novel psychedelics (psilocybin, MDMA, DMT, mescaline and most tryptamines) are controlled and have no routine medical/reimbursed use outside approved clinical research. Esketamine (Spravato) is authorised in the EU and has been the subject of Swedish health-economics assessment; access is limited to specialist psychiatry with supervised administration and regional/clinic-level funding decisions.
Country Details
- Region
- Europe
- Last updated
- 4 May 2026
Country Report
Medical Only (Private)Medical Access and Reimbursement
Sweden maintains a restrictive narcotics framework: classical and novel psychedelics (psilocybin, MDMA, DMT, mescaline and most tryptamines) are controlled and have no routine medical/reimbursed use outside approved clinical research. Esketamine (Spravato) is authorised in the EU and has been the...
Open access guide →Psychedelic Stakeholders in Sweden
Organisations, sponsors, clinics, and research groups connected to psychedelic science in Sweden.
29k International AB
Sweden
CTC Clinical Trial Consultants AB
Sweden
European Commission (Horizon Europe)
European Medicines Agency (EMA)
European Union Drugs Agency (EUDA)
HumanKindLabs
Sweden
Karolinska Institutet
Sweden
Norrsken Mind
Sweden
PSIPET Research Group
Karolinska Institute
Region Örebro County
Sweden
Stockholm University
Sweden
Vastra Gotaland Region
Research Events in Sweden
Conferences, trainings, and research gatherings connected to the country report.
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Sweden.